<DOC>
	<DOCNO>NCT00776074</DOCNO>
	<brief_summary>The purpose study determine pharmacodynamics leuprorelin gelatin free formulation ( GF ) leuprorelin gelatin contain formulation ( GC ) female subject uterine fibroid .</brief_summary>
	<brief_title>A Pharmacodynamic Study Leuprorelin Gelatin-Free Formulation Female Subjects With Uterine Fibroids .</brief_title>
	<detailed_description>Gonadotropin-releasing hormone , also call luteinizing hormone release hormone , neuropeptide hormone release hypothalamus . Gonadotropin-releasing hormone bind specific gonadotropin-releasing hormone receptor cell membrane pituitary gland cell , induce cell produce release gonadotropin : luteinizing hormone follicle-stimulating hormone . Luteinizing hormone follicle-stimulating hormone release general circulation stimulate gonad produce release sex steroid : testosterone estrogen . Follicle-stimulating hormone also control gametogenesis . Suppression gonadotropin secretion effective treatment condition prostate cancer , endometriosis central precocious puberty , condition respond manipulation sex steroid . Suppression gonadotropin secretion achieve administration gonadotropin-releasing hormone agonist , initial transient stimulation gonadotropin release , reversibly desensitize pituitary gonadotropin-releasing hormone receptor . Desensitization think occur down-regulation number gonadotropin-releasing hormone receptor uncouple receptor biochemical pathway lead gonadotropin release . Termination gonadotropin-releasing hormone agonist administration reverse desensitization , gonadotropin sex hormone level return normal . There several market gonadotropin-releasing hormone agonist , one TAP-144 ( leuprorelin ) , active synthetic nonapeptide gonadotropin-releasing hormone analogue . In present study , exist leuprorelin 1- month sustain release formulation compare new gelatin-free 1-month sustained release formulation .</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Female patient measurable uterine fibroid confirm vaginal abdominal ultrasound , deem otherwise healthy . A body mass index range 18 28 . Oestradiol , progesterone , luteinizing hormone follicle stimulate hormone result within range normal ovarian function . Regular menstruation ( except symptom fibroid ) . Females childbearing potential sexually active must agree use barrier contraception , neither pregnant lactating Screening throughout duration study . Acute pelvioperitonitis , ovarian cyst , persistent corpus luteum . History bilateral oophorectomy , hysterectomy , hypophysectomy . Clinically relevant abnormal history , physical finding , laboratory value prestudy screen assessment could interfere objective study safety patient . Presence acute chronic illness history chronic illness sufficient invalidate patient participation study make unnecessarily hazardous . Impaired endocrine , thyroid , hepatic , respiratory renal function , diabetes mellitus , coronary heart disease , history psychotic mental illness . Presence history severe adverse reaction drug . Participation clinical study new chemical entity prescription medicine within previous 3 month . Presence history drug alcohol abuse , smoke 10 cigarette daily . Evidence drug abuse urine testing . Positive test hepatitis B , hepatitis C , human immune deficiency virus 1 human immune deficiency virus 2 . Severe bleeding fibroid . Anemia ( hemoglobin le 11 g/dL ) , loss 400 mL blood 3 month study . Use oral contraceptive estrogen contain medication , progestin , danazol , progesterone antagonist , antiandrogens , steroid gonadotropin might affect sex steroid production activity assay ( e.g . norethindrone ) within 30 day prior study enrolment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Leiomyoma</keyword>
	<keyword>Uterine Fibroids</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Uterine Neoplasms</keyword>
	<keyword>Fibroid Tumor</keyword>
</DOC>